MHRA Renews Recall of Counterfeit Lipitor

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The UK Medicines and Healthcare Products Regulatory Agency (MHRA, London) has reissued its recall of a specific batch of counterfeit ?Lipitor? 20-mg tablets. MHRA, in conjunction with Pfizer (New York City, NY), first issued the recall of batch number 004405K1 in July 2005. The new recall is in response to the discovery of more packages of the counterfeit drug in the United Kingdom.

The UK Medicines and Healthcare Products Regulatory Agency (MHRA, London, www.mhra.gov.uk) has reissued a recall of a specific batch of counterfeit “Lipitor” 20-mg tablets. MHRA, in conjunction with Pfizer (New York City, NY, www.pfizer.com), first issued the recall of batch number 004405K1 in July 2005. The new recall is in response to the discovery of more packages of the counterfeit drug in the United Kingdom.

Mick Deats, MHRA’s head of enforcement and intelligence, said that testing of the counterfeit product revealed “no immediate risk to patients,” but added that the agency “cannot guarantee its quality.” MHRA therefore advises patients to stop taking tablets from the recalled batch and to discuss possible side effects with a doctor. Patients who have packages of 20-mg Lipitor tablets with batch number 004405K1 are urged to contact their pharmacists.

Lipitor is Pfizer’s prescription medicine for lowering cholesterol and reducing patients’ risk of cardiovascular disease. The company is coordinating the collection of the recalled batch on behalf of MHRA.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes